Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 2/2017

01-02-2017 | Editorial

Treatment of severe MRSA infections: current practice and further development

Authors: José-Artur Paiva, Philippe Eggimann

Published in: Intensive Care Medicine | Issue 2/2017

Login to get access

Excerpt

Staphylococcus aureus is one of the “ESKAPE pathogens”, considered to require urgent development of new therapies, in spite of some decline in the incidence of methicillin-resistant S. aureus (MRSA) infections. Vancomycin, a glycopeptide with an excellent spectrum of activity against Gram-positive pathogens through inhibition of cell wall synthesis, has been the mainstay of treatment for MRSA. However, MRSA infections are associated with increased morbidity and mortality, when compared with methicillin-sensitive S. aureus (MSSA), and several weaknesses have been identified related to vancomycin use, namely slower bacterial killing than oxacillin, poor penetration in the lungs and central nervous system, and frequent underdosage in critically ill patients as a result of increased volume of distribution and renal hyperfiltration [1]. …
Literature
1.
de Gatte MDMF, Revilla N, Calvo MV, Dominquez-Gil A, Sanchez-Navarro A (2007) Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med 33:279–285CrossRef
2.
Rybak MJ, Lomaestro BM, Rotscahfer JC, Moellering RC et al (2009) Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49:325–327CrossRefPubMed
3.
Van Hal SJ, Lodise TP, Paterson DL (2012) The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 54:755–771CrossRefPubMed
4.
Holmes NE, Turnidge JD, Munckhof WJ et al (2011) Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 204(3):340–347CrossRefPubMed
5.
Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N (2012) Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 67(1):17–24CrossRefPubMed
6.
Liu C, Bayer A, Cosgrove SE et al (2011) Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52(3):e18–e55CrossRefPubMed
7.
Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54(5):621–629CrossRefPubMed
8.
Jiang H, Tang RN, Wang J (2013) Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomized controlled trials. Eur J Clin Microbiol Infect Dis 32(9):1121–1128CrossRefPubMed
9.
Murray KP, Zhao JJ, Davis SL et al (2013) Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration > 1 mg/L: a matched cohort study. Clin Infect Dis 56:1562–1569CrossRefPubMed
10.
Gould IM, Miró JM, Rybak MJ (2013) Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 42(3):202–210CrossRefPubMed
11.
Schweizer ML, Furuno JP, Harris AD et al (2011) Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 11:279CrossRefPubMedPubMedCentral
12.
Holmes NE, Tong SYC, Davis JS, van Hal SJ (2015) Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond. Semin Respir Crit Care Med 36:17–30CrossRefPubMed
13.
Montravers P, Dupont H, Bedos J-P et al (2014) Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting. Intensive Care Med 40:988–997CrossRefPubMedPubMedCentral
14.
Dilworth TJ, Ibrahim O, Hall P, Sliwinski J et al (2014) β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone. Antimicrob Agents Chemother 58:102–109CrossRefPubMedPubMedCentral
15.
Davis JS, Sud A, O’Sullivan MV, Robinson JO et al (2016) Combination of vancomycin and β-Lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis 62(2):173–180CrossRefPubMed
16.
Gillet Y, Dumitrescu O, Tristan A, Dauwalder O et al (2011) Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob Agents 38(6):457–464CrossRefPubMed
17.
François B, Chastre J, Eggiman P, Laterre PF et al (2016) The SAATELLITE and EVADE clinical studies within the COMBACTE consortium: a public-private collaborative effort in designing and performing clinical trials for novel antibacterial drugs to prevent nosocomial pneumonia. Clin Infect Dis 63(Suppl 2):S46–S51CrossRefPubMed
Metadata
Title
Treatment of severe MRSA infections: current practice and further development
Authors
José-Artur Paiva
Philippe Eggimann
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 2/2017
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-016-4572-4

Other articles of this Issue 2/2017

Intensive Care Medicine 2/2017 Go to the issue

Original

High flow nasal cannula (HFNC) versus nasal continuous positive airway pressure (nCPAP) for the initial respiratory management of acute viral bronchiolitis in young infants: a multicenter randomized controlled trial (TRAMONTANE study)

Editorial

Ventilation-induced lung injury exists in spontaneously breathing patients with acute respiratory failure: No

What's New in Intensive Care

Ten things to know about critically ill elderly patients

Letter

Randomised trials of vitamin D3 for critically ill patients in adults: systematic review and meta-analysis with trial sequential analysis

Letter

ABO type and bleeding during adult ECMO

Editorial

Fluid management in the ICU: has the tide turned?